blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1170380

EP1170380 - Methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening [Right-click to bookmark this link]
Former [2002/02]Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
[2009/21]
StatusNo opposition filed within time limit
Status updated on  10.09.2010
Database last updated on 16.09.2024
Most recent event   Tooltip28.09.2012Lapse of the patent in a contracting state
New state(s): NL		published on 31.10.2012  [2012/44]
Applicant(s)For all designated states
Monogram BioSciences, Inc.
345 Oyster Point Boulevard
South San Francisco, CA 94080-1913 / US
[2009/45]
Former [2006/32]For all designated states
Monogram Biosciences, Inc.
345 Oyster Point Boulevard
South San Francisco, CA 94080-1913 / US
Former [2002/02]For all designated states
Virologic, Inc.
270 East Grand Avenue
South San Francisco, CA 94080 / US
Inventor(s)01 / Capon, Daniel J.
90 Woodbridge Road
Hillsborough, CA 94010 / US
02 / Petropoulous, Christos, John
415 Garcia Avenue
Half Moon Bay, CA 94019 / US
 [2004/01]
Former [2002/02]01 / Capon, Daniel J.
90 Woodbridge Road
Hillsborough, CA 94010 / US
02 / Petropoulous, Christos, John
415 Garcia Avenue
Half Moon Bay, CA 94019 / US
Representative(s)Tollervey, Rebecca Marie, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
[N/P]
Former [2009/23]Tollervey, Rebecca Marie, et al
Mewburn Ellis LLP 33 Gutter Lane London
EC2V 8AS / GB
Former [2006/22]Hodsdon, Stephen James
Mewburn Ellis LLP York House 23 Kingway
London WC2B 6HP / GB
Former [2006/15]Ricker, Mathias, et al
Jones Day, Rechtsanwälte, Attorneys-at-Law, Patentanwälte, Prinzregentenstrasse 11
80538 München / DE
Former [2002/02]Denison, Christopher Marcus, et al
Mewburn Ellis York House 23 Kingsway
London WC2B 6HP / GB
Application number, filing date01117002.429.01.1997
[2002/02]
Priority number, dateUS1996059300929.01.1996         Original published format: US 593009
[2002/02]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP1170380
Date:09.01.2002
Language:EN
[2002/02]
Type: A3 Search report 
No.:EP1170380
Date:02.05.2003
[2003/18]
Type: B1 Patent specification 
No.:EP1170380
Date:04.11.2009
Language:EN
[2009/45]
Search report(s)(Supplementary) European search report - dispatched on:EP19.03.2003
ClassificationIPC:C12Q1/68, C12Q1/70, C12Q1/02, C12N15/64
[2002/02]
CPC data not yet available
Designated contracting statesAT,   BE,   CH,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2002/02]
Extension statesAL31.07.2001
LT31.07.2001
LV31.07.2001
RO31.07.2001
SI31.07.2001
TitleGerman:Verfahren zur Bestimmung antiviraler Wirkstoff Suszeptibilität und Resistenz sowie antivirales Wirkstoff-Screening[2009/21]
English:Methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening[2009/21]
French:Méthodes déterminant une susceptibilité et résistance anti-virale et screening pour des agents anti-viraux[2009/21]
Former [2002/02]Zusammensetzungen und Verfahren zur Bestimmung antiviraler Wirkstoff Suszeptibilität und Resistenz sowie antivirales Wirkstoff-Screening
Former [2002/02]Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
Former [2002/02]Compositions et méthodes déterminant une susceptibilité et résistance anti-virale et screening pour des agents anti-viraux
Examination procedure31.10.2003Examination requested  [2004/01]
07.11.2005Despatch of a communication from the examining division (Time limit: M08)
17.07.2006Reply to a communication from the examining division
17.12.2007Despatch of a communication from the examining division (Time limit: M06)
16.06.2008Reply to a communication from the examining division
19.05.2009Communication of intention to grant the patent
17.09.2009Fee for grant paid
17.09.2009Fee for publishing/printing paid
Parent application(s)   TooltipEP97907549.6  / EP0852626
Opposition(s)05.08.2010No opposition filed within time limit [2010/41]
Fees paidRenewal fee
31.07.2001Renewal fee patent year 03
31.07.2001Renewal fee patent year 04
31.07.2001Renewal fee patent year 05
19.12.2001Renewal fee patent year 06
11.12.2002Renewal fee patent year 07
14.01.2004Renewal fee patent year 08
27.01.2005Renewal fee patent year 09
12.01.2006Renewal fee patent year 10
26.01.2007Renewal fee patent year 11
25.01.2008Renewal fee patent year 12
30.01.2009Renewal fee patent year 13
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT04.11.2009
BE04.11.2009
DK04.11.2009
FI04.11.2009
IT04.11.2009
NL04.11.2009
SE04.11.2009
IE29.01.2010
LU29.01.2010
CH31.01.2010
LI31.01.2010
GR05.02.2010
ES15.02.2010
PT04.03.2010
MC31.05.2010
[2012/44]
Former [2012/43]AT04.11.2009
BE04.11.2009
DK04.11.2009
FI04.11.2009
IT04.11.2009
SE04.11.2009
IE29.01.2010
LU29.01.2010
CH31.01.2010
LI31.01.2010
GR05.02.2010
ES15.02.2010
PT04.03.2010
MC31.05.2010
Former [2011/14]AT04.11.2009
BE04.11.2009
DK04.11.2009
FI04.11.2009
IT04.11.2009
SE04.11.2009
IE29.01.2010
CH31.01.2010
LI31.01.2010
GR05.02.2010
ES15.02.2010
PT04.03.2010
MC31.05.2010
Former [2011/07]AT04.11.2009
BE04.11.2009
DK04.11.2009
FI04.11.2009
SE04.11.2009
IE29.01.2010
CH31.01.2010
LI31.01.2010
GR05.02.2010
ES15.02.2010
PT04.03.2010
MC31.05.2010
Former [2011/03]AT04.11.2009
BE04.11.2009
DK04.11.2009
FI04.11.2009
SE04.11.2009
CH31.01.2010
LI31.01.2010
GR05.02.2010
ES15.02.2010
PT04.03.2010
MC31.05.2010
Former [2010/47]AT04.11.2009
BE04.11.2009
DK04.11.2009
FI04.11.2009
SE04.11.2009
CH31.01.2010
LI31.01.2010
GR05.02.2010
ES15.02.2010
PT04.03.2010
Former [2010/35]AT04.11.2009
BE04.11.2009
DK04.11.2009
FI04.11.2009
SE04.11.2009
ES15.02.2010
PT04.03.2010
Former [2010/31]AT04.11.2009
BE04.11.2009
FI04.11.2009
SE04.11.2009
ES15.02.2010
PT04.03.2010
Former [2010/30]AT04.11.2009
FI04.11.2009
SE04.11.2009
ES15.02.2010
PT04.03.2010
Former [2010/22]FI04.11.2009
SE04.11.2009
ES15.02.2010
PT04.03.2010
Former [2010/19]ES15.02.2010
Documents cited:Search[Y]EP0291893  (DU PONT [US]) [Y] 1,3-5,9,10,13,17,18,20-22,29,31-33,36,46,65,66,70,73,75,77-79,81,82 * the whole document *;
 [XY]EP0361749  (DANA FARBER CANCER INST INC [US]) [X] 1,3-8,10,14,17-22,29,31-33,35,36,46-50 * the whole document * [Y] 51-54,65-73,75,77-79,81,82;
 [XY]EP0372904  (UNIV OSAKA RES FOUND [JP]) [X] 17,18,21 * the whole document * [Y] 1,3,5,9,29,31-33,65,66,70,73,75,77-79,81,82;
 [A]EP0414475  (CHIRON CORP [US]) [A] * the whole document *;
 [A]FR2700169  (TRANSGENE SA [FR]) [A] * the whole document *;
 [Y]WO9505453  (SYSTEMIX INC [US], et al) [Y] 1,29,51-54,65,75,79 * the whole document *;
 [DA]WO9522622  (UNIV WASHINGTON [US]) [DA] * the whole document *;
 [XY]WO9529703  (NABEL GARY J [US], et al) [X] 17,18,20,21 * abstract * * page 2, line 1 - line 15 * * page 31, line 18 - page 35, line 4 * * page 40, line 5 - page 41, line 25; claims 1-24 * [Y] 1,3-8,10,13,14,16,19,29,31-33,35,36,46-50,65,66,70,72;
 [XY]WO9530763  (VIAGENE INC [US]) [X] 24-26 * abstract * [Y] 1,3,5-8,14,16-22,29,31-33,35,48-51,67-72;
 [T]US5837464  (CAPON DANIEL [US], et al) [T] 1-82 * the whole document *;
 [T]WO9906597  (VIROLOGIC INC [US]) [T] 1-82* the whole document *;
 [X]  - KELLAM P ET AL, "RECOMBINANT VIRUS ASSAY: A RAPID, PHENOTYPIC ASSAY FOR ASSESSMENT OF DRUG SUSCEPTIBILITY OF HUMAN IMMUNODEFIENCY VIRUS TYPE 1 ISOLATES", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, (199401), vol. 38, no. 1, ISSN 0066-4804, pages 23 - 30, XP000952459 [X] 1,3,17,18,29,31,51-54,65,75,79 * the whole document *
 [X]  - MORGENSTERN J P ET AL, "ADVANCED MAMMALIAN GENE TRANSFER: HIGH TITRE RETROVIRAL VECTORS WITH MULTIPLE DRUG SELECTION MARKERS AND A COMPLEMENTARY HELPER -FREE PACKAGING CELL LINE", NUCLEIC ACIDS RESEARCH, (19900101), vol. 18, no. 12, pages 3587 - 3596, XP002073969 [X] 17-22,24-26 * the whole document *
 [DXY]  - KELLAM P ET AL., "Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, (1992), vol. 89, pages 1934 - 1938, XP002107338 [DX] 17,18,20 * abstract * * page 1934, column 1, paragraph 1 - page 1935, column 1, paragraph 5; figures 1,4 * [Y] 1,3,29,31,46,47,51-54,65,66,70,72,75,77-79,81,82

DOI:   http://dx.doi.org/10.1073/pnas.89.5.1934
 [A]  - SALTARELLI M J ET AL, "THE CAEV TAT GENE TRANS-ACTIVATES THE VIRAL LTR AND IS NECESSARY FOR EFFICIENT VIRAL REPLICATION", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, (1993), vol. 197, ISSN 0042-6822, pages 35 - 44, XP001059850 [A] * the whole document *

DOI:   http://dx.doi.org/10.1006/viro.1993.1564
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.